Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The anticoagulants market.

Literature DB >> 19390569

The anticoagulants market.

Irena Melnikova.

Abstract

Mesh：

Substances：
Anticoagulants

Year: 2009 PMID： 19390569 DOI： 10.1038/nrd2851

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

× No keyword cloud information.

2 in total

1. Dabigatran etexilate.

Authors: Bengt I Eriksson; Helen Smith; Uma Yasothan; Peter Kirkpatrick
Journal: Nat Rev Drug Discov Date: 2008-07 Impact factor: 84.694

Review 2. Triggers, targets and treatments for thrombosis.

Authors: Nigel Mackman
Journal: Nature Date: 2008-02-21 Impact factor: 49.962

2 in total

15 in total

1. Dendrigraft of Poly-l-lysine as a Promising Candidate To Reverse Heparin-based Anticoagulants in Clinical Settings.

Authors: Benjamin Ourri; Jean-Patrick Francoia; Gerald Monard; Jean-Christophe Gris; Julien Leclaire; Laurent Vial
Journal: ACS Med Chem Lett Date: 2019-05-08 Impact factor: 4.345

Review 2. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.

Authors: Michael Ganetsky; Kavita M Babu; Steven D Salhanick; Robert S Brown; Edward W Boyer
Journal: J Med Toxicol Date: 2011-12

3. Homogeneous low-molecular-weight heparins with reversible anticoagulant activity.

Authors: Yongmei Xu; Chao Cai; Kasemsiri Chandarajoti; Po-Hung Hsieh; Lingyun Li; Truong Q Pham; Erica M Sparkenbaugh; Juzheng Sheng; Nigel S Key; Rafal Pawlinski; Edward N Harris; Robert J Linhardt; Jian Liu
Journal: Nat Chem Biol Date: 2014-02-23 Impact factor: 15.040

The anticoagulants market.

1. Dabigatran etexilate.

Review 2. Triggers, targets and treatments for thrombosis.

1. Dendrigraft of Poly-l-lysine as a Promising Candidate To Reverse Heparin-based Anticoagulants in Clinical Settings.

Review 2. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.

3. Homogeneous low-molecular-weight heparins with reversible anticoagulant activity.

4. Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin.

Review 5. Emerging principles in protease-based drug discovery.

6. In Silico Design of Novel Anticoagulant Peptides targeting Blood Coagulation Factor VIIa.

7. Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase.

8. Structure and behavior of human α-thrombin upon ligand recognition: thermodynamic and molecular dynamics studies.

Review 9. Serine Proteases of Malaria Parasite Plasmodium falciparum: Potential as Antimalarial Drug Targets.

10. Warfarin pharmacogenetics: challenges and opportunities for clinical translation.